Market Overview

Sage Therapeutics to Present at Canaccord 38th Annual Growth Conference


Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that the Company will
present at the Canaccord 38th Annual Growth Conference on Wednesday,
August 8, 2018 at 11:00 A.M. ET in Boston, MA.

A live webcast of the presentation can be accessed on the investor page
of Sage's website at A replay of the webcast will
also be archived for up to 30 days on Sage's website following the

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering CNS disorders. Sage has a portfolio of novel
product candidates targeting critical CNS receptor systems, GABAA
and NMDA. Sage's lead program, a proprietary IV formulation of
brexanolone (SAGE-547), has completed Phase 3 clinical development for
postpartum depression and a New Drug Application is currently under
review with the U.S. Food and Drug Administration. Sage is developing
its next generation modulators, including SAGE-217 and SAGE-718, in
various CNS disorders. For more information, please visit

View Comments and Join the Discussion!